Table 1.
The characteristic of studies based on the type of interventions
| Pharmacological Number (%) | Supplemental Number (%) | Herbal Number (%) | Nutritional Number (%) | Others Number (%) | Total Number (%) | ||
|---|---|---|---|---|---|---|---|
| Study characteristics | Parallel | 50 (92.6) | 51 (96.2) | 28 (93.3) | 12 (52.2) | 25 (100) | 166 (90) |
| cross-over | 4 (7.4) | 2 (3.8) | 2 (6.7) | 11 (47.8) | 0 | 19 (10) | |
| Year of publication | <2005 | 9 (16.7) | 6 (11.3) | 4 (13.5) | 4 (17.4) | 1 (4) | 24 (13) |
| 2005–2006 | 7 (13) | 1 (1.9) | 2 (6.7) | 2 (8.7) | 2 (8) | 14 (7) | |
| 2007–2008 | 9 (16.7) | 15 (28.3) | 5 (16.7) | 4 (17.4) | 5 (20) | 38 (20) | |
| 2009–2010 | 13 (24.1) | 14 (26.4) | 7 (23.3) | 3 (13) | 11 (44) | 48 (27) | |
| >2011 | 16 (29.) | 17 (32.1) | 12 (40) | 10 (43.5) | 6 (24) | 61 (33) | |
| Type of diabetes | Type 1 | 4 (7.4) | 4 (7.5) | 0 | 1 (4.3) | 0 | 9 (5) |
| Type 2 | 40 (74.1) | 46 (86.8) | 29 (96.7) | 21 (91.3) | 8 (32) | 137 (75) | |
| Type 1 & 2 | 1 (1.9) | 0 | 0 | 0 | 2 (8) | 10 (5) | |
| Not mentioned | 9 (16.7) | 3 (5.7) | 1 (3.3) | 1 (4.3) | 15 (60) | 29 (15) | |
| Study duration (weeks) | <1 | 2 (3.7) | 1 (1.9) | 1 (3.3) | 0 | 0 | 4 (2) |
| 1–5 | 6 (11.1) | 0 | 7 (23.3) | 2 (8.7) | 4 (16) | 19 (10) | |
| 5–10 | 10 (18.5) | 22 (41.5) | 14 (46.7) | 12 (52.2) | 3 (12) | 51 (28) | |
| 10–15 | 20 (37) | 24 (45.3) | 4 (13.3) | 3 (13) | 6 (24) | 57 (30) | |
| 15–20 | 6 (11) | 2 (3.8) | 3 (10) | 4 (17.4) | 4 (16) | 19 (10) | |
| 20–25 | 7 (13) | 1 (1.9) | 1 (3.3) | 1 (4.3) | 7 (28) | 17 (9) | |
| >25 | 3 (5.6) | 3 (5.7) | 0 | 1 (4.3) | 1 (4) | 8 (4) | |
| Estimation of sample size | <20 | 3 (5.6) | 0 | 3 (10) | 6 (26.1) | 0 | 12 (6) |
| 20–40 | 12 (22.2) | 10 (18.9) | 2 (6.7) | 4 (17.4) | 4 (1) | 32 (17) | |
| 40–60 | 17 (31.5) | 18 (34) | 12 (40) | 8 (34.8) | 8 (32) | 63 (35) | |
| 60–80 | 10 (18.5) | 13 (24.5) | 7 (23.3) | 4 (17.4) | 8 (32) | 42 (23) | |
| 80–100 | 4 (7.4) | 8 (15.1) | 5 (16.7) | 1 (4.3) | 2 (8) | 20 (11) | |
| >100 | 8 (14.8) | 4 (7.5) | 1 (3.3) | 0 | 3 (12) | 16 (8) | |
| IRB approval, informed consent | Yes | 53 (98.1) | 53 (100) | 29 (96.7) | 23 (100) | 24 (96) | 182 (99) |
| No | 1 (1.9) | 0 | 1 (3.3) | 0 | 1 (4) | 3 (1) |